Platelet P2Y12 receptor inhibition by thienopyridines: status and future

Bibliography

• Fuster V, Stein B, Ambrose JA, et al. Atherosclerotic plaque rupture and thrombosis. Evolving concepts. Circulation 1990;82:47-59
   Web of Science ®Google Scholar
• Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007;357:2482-94
   PubMed Web of Science ®Google Scholar
• Murugappan S, Shankar H, Kunapuli SP. Platelet receptors for adenine nucleotides and thromboxane A2. Semin Thromb Hemost 2004;30(4):411-8
   PubMed Web of Science ®Google Scholar
• Jagroop IA, Burnstock G, Mikhailidis DP. Both the ADP receptors P2Y1 and P2Y12, play a role in controlling shape change in human platelets. Platelets 2003;14(1):15-20
   PubMed Web of Science ®Google Scholar
• Pereillo JM, Maftouh M, Andrieu A, Picard C. Structure and stereochemistry of the active metabolite of Clopidogrel. Drug Metab Dispos 2002;30:1288-95
   PubMed Web of Science ®Google Scholar
• Herbert JM. Clopidogrel and antiplatelet therapy. Expert Opin Investig Drugs 1994;3:449-55
   Google Scholar
• Weber AA, Braun M, Hohlfeld T, et al. Recovery of platelet function after discontinuation of Clopidogrel treatment in healthy volunteers. Br J Clin Pharmacol 2001;52:333-6
   PubMed Web of Science ®Google Scholar
• Savi P, Pflieger AM, Herbert JM. cAMP is not an important messenger for ADP-induced platelet aggregation. Blood Coagul Fibrinolysis 1996;7:249-52
   PubMed Web of Science ®Google Scholar
• Soulet C, Sauzeau V, Plantavid M, et al. Gi-dependent and -independent mechanisms downstream of the P2Y12 ADP receptor. J Thromb Haemost 2004;2:135-46
   PubMed Web of Science ®Google Scholar
• Savi P, Zachayus JL, Delesque-Touchard N, et al The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipids rafts. Proc Natl Acad Sci USA 2006;103:11069-74
   PubMed Web of Science ®Google Scholar
• Ding Z, Bynagari YS, Mada SR, et al. Studies on the role of the extracellular cysteines and oligomeric structures of the P2Y12 receptor when interacting with antagonists. J Thromb Haemost 2009;7:232-4
   PubMed Web of Science ®Google Scholar
• Mazoyer E, Ripoll L, Boisseau MR, Drouet L. How does Ticlopidine treatment lower plasma fibrinogen? Thromb Res 1994;75:361-70
   PubMed Web of Science ®Google Scholar
• Hayakawa M, Kuzuya F. Effects of Ticlopidine on erythrocyte aggregation in thrombotic disorders. Angiology 1991;42:747-53
   PubMed Web of Science ®Google Scholar
• Hermann A, Rauch BH, Braun M, et al. Platelet CD40 ligand (CD40L)–subcellular localization, regulation of expression, and inhibition by Clopidogrel. Platelets 2001;12:74-82
   PubMed Web of Science ®Google Scholar
• Klinkhardt U, Bauersachs R, Adams J, et al. Clopidogrel but not Aspirin reduces P-selectin expression and formation of platelet–leukocyte aggregates in patients with atherosclerotic vascular disease. Clin Pharmacol Ther 2003;73:232-41
   PubMed Web of Science ®Google Scholar
• Klinkhardt U, Graff J, Harder S. Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P selectin expression in a human ex vivo in vitro model. Clin Pharmacol Ther 2002;71:176-85
   PubMed Web of Science ®Google Scholar
• de Loeril M, Bordet JC, Salen P, et al. Ticlopidine increases nitric oxide generation in heart-transplant recipients: a possible novel property of Ticlopidine. J Cardiovasc Pharmacol 1998;32:225-30
   PubMed Web of Science ®Google Scholar
• Arrebola MM, De la Cruz JP, Villalobos MA, et al. In vitro effects of Clopidogrel on the platelet–subendothelium interaction, platelet thromboxane and endothelial prostacyclin production, and nitric oxide synthesis. J Cardiovasc Pharmacol 2004;43:74-82
   PubMed Web of Science ®Google Scholar
• Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;2:442-3
   Google Scholar
• Limet R, David JL, Magotteaux P, et al. Prevention of aorta-coronary bypass graft occlusion. Beneficial effect of Ticlopidine on early and late patency rates of venous coronary bypass grafts: a double-blind study. J Thorac Cardiovasc Surg 1987;94:773-83
   PubMed Web of Science ®Google Scholar
• Janzon L, Bergqvist D, Boberg J, Kjellström T. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of Ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med 1990;227:301-8
   PubMed Web of Science ®Google Scholar
• Hass WK, Easton JD, Adams HP Jr, et al. A randomized trial comparing Ticlopidine hydrochloride with Aspirin for the prevention of stroke in high risk patients. N Engl J Med 1989;321:501-7
   PubMed Web of Science ®Google Scholar
• Scrutinio D, Cimminiello C, Marubini E, et al. Ticlopidine versus Aspirin after myocardial infarction (STAMI) trial. J Am Coll Cardiol 2001;37:1259-65
   PubMed Web of Science ®Google Scholar
• Schünlen H, Hadamitzky M, Walter H, et al. Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmar-Schatz stent placement: analysis of a prospective risk stratification protocol in the Intracoronary Stenting and Antithrombotic Regimen (ISAR) trial. Circulation 1997;95:2015-21
   PubMed Web of Science ®Google Scholar
• Urban P, Macaya C, Rupprecht HJ, Pieper M. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting (MATTIS). Circulation 1998;98;2126-32
   PubMed Web of Science ®Google Scholar
• Bertrand ME, Legrand V, Boland J, McFadden EP. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: the Full Anticoagulation Versus Aspirin and Ticlopidine (FANTASTIC) Study. Circulation 1998;98;1597-603
   PubMed Web of Science ®Google Scholar
• Cutlip DE, Leon MB, Ho KKL, Baim DS. Acute and nine-month clinical outcomes after “suboptimal” coronary stenting results from the STent Anti-thrombotic Regimen Study (STARS) Registry. J Am Coll Cardiol 1999;34:698-706
   PubMed Web of Science ®Google Scholar
• Bertrand ME, Rupprecht HS, Urban P, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 2000;102;624-9
   PubMed Web of Science ®Google Scholar
• CAPRIE Steering Committee. A randomised, blinded, trial of Clopidogrel versus Aspirin in patients at risk of ischaemic events. Lancet 1996;348:1329-39
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, et al. Effects of Clopidogrel in addition to Aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502
   PubMed Web of Science ®Google Scholar
• Chen ZM, Jiang LX, Chen YP, et al. Addition of Clopidogrel to Aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607-21
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Cannon CP, Gibson CM, et al. Addition of Clopidogrel to Aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-89
   PubMed Web of Science ®Google Scholar
• Mehta SR, Yusuf S, Peters RJG, et al. Effects of pretreatment with Clopidogrel and Aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Cannon CP, Gibson CM, et al. Effect of Clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005;294:1224-32
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20. Erratum in: JAMA 2003;289:987
   PubMed Web of Science ®Google Scholar
• Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and Clopidogrel compared with Clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331-7
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Fox KAA, Hacke W, Topol EJ. Clopidogrel and Aspirin versus Aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17
   PubMed Web of Science ®Google Scholar
• Sacco RL, Diener HC, Yusuf S, et al. Aspirin and extended-release dipyridamole versus Clopidogrel for recurrent stroke. N Engl J Med 2008;359:1238-51
   PubMed Web of Science ®Google Scholar
• Connolly S, Pogue J, Hart R, et al. Clopidogrel plus Aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Event (ACTIVE W): a randomizaed controlled trial. Lancet 2006;367:1903-12
   PubMed Web of Science ®Google Scholar
• Matsagas M, Jagroop IA, Geroulakos G, Mikhailidis DP. The effect of a loading dose (300 mg) of Clopidogrel on platelet function in patients with peripheral arterial disease. Clin Appl Thromb Hemost 2003;9:115-20
   PubMed Web of Science ®Google Scholar
• CASPAR: Clopidogrel and Acetyl Salicylic Acid in Bypass Surgery for Peripheral ARterial Disease. Available from: http://clinicaltrials.gov/show/NCT00174759 [Last access 11 March 2009]
   Google Scholar
• Peripheral Vascular research: Camper Trial: drug research offered after peripheral angioplasty and/or stent placement. Minneapolis heart institute. Available from: http://www.mplsheart.com/Publications/Research/PeripheralVascularResearch/PeripheralVascularArchives/PVRCamperTrial.aspx [Last access 11 March 2009]
   Google Scholar
• Fox K, Garcia MAA, Ardissino D, et al. The task force on the management of stabele angina pectoris of the European Society of Cardiology. Guidelines of the management of the stable angina pectoris: full text. Eur Heart J 2006;27:1341-81
   PubMed Web of Science ®Google Scholar
• Patrono C, Bachmann F, Baigent C, De Caterina R, et al. The task force on the use of antiplatelet agents in patients with atherosclerosis cardiovascular disease of the European Society of Cardiology. Expert consensus documents on the use of antiplatelet agents. Eur Heart J 2004;25:166-81
   PubMed Web of Science ®Google Scholar
• Bassand JP, Hamm WC, Ardissino D, et al. The task force for the diagnosis and treatment of the non-ST-segment elevation acute coronary syndromes of the European Society of Cardiology. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007;28:1598-660
   PubMed Web of Science ®Google Scholar
• Van de Werf F, Bax J, Betriu A, et al. The task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting persistent ST-segement elevation. Eur Heart J 2008;28:2909-45
   Web of Science ®Google Scholar
• Berger JS, Frye CB, Harshaw Q, et al. Impact of Clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis. J Am Coll Cardiol 2008;52:1693-701
   PubMed Web of Science ®Google Scholar
• Montalescot G, Sideris G, Meuleman C, et al. A randomized comparison of high Clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 2006;48:931-8
   PubMed Web of Science ®Google Scholar
• King SB III, Smith SC Jr, Hirsfeld JW Jr, et al. American college of cardiology/American Heart Association task force on practice guidelines. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. J Am Coll Cardiol 2008;51:172-209
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to Clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007;49:1505-16
   PubMed Web of Science ®Google Scholar
• Dorsam RT, Murugappan S, Ding Z, Kunapuli SP. Clopidogrel: interactions with the P2Y12 receptor and clinical relevance. Hematology 2003;8:359-65
   PubMedGoogle Scholar
• Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001;409:202-7
   PubMed Web of Science ®Google Scholar
• Fontana P, Dupont A, Gandrille S, et al. Adenosine diphosphate-induced platelet aggregation in associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003;108:989-95
   PubMed Web of Science ®Google Scholar
• Brugaletta S, Porto I. Pharmacogenetic modulation of platelet inhibition. Curr Pharmacogenomics Personalized Med 2008;6:171-84
   Web of Science ®Google Scholar
• Klinkhardt U, Dragutinovic I, Harder S. P-selectin (CD62p) and P-selectin glycoprotein ligand-1 (PSGL-1) polymorphisms: minor phenotypic differences in the formation of platelet-leukocyte aggregates and response to Clopidogrel. Int J Clin Pharmacol Ther 2005;43:255-63
   PubMed Web of Science ®Google Scholar
• Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A4-mediated metabolism. Adv Drug Deliv Rev 2002;54:1271-94
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to Clopidogrel. N Engl J Med 2009;360:354-62
   PubMed Web of Science ®Google Scholar
• Simon T, Verstuyft C, Mary-Krause M, et al. French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to Clopidogrel and cardiovascular events. N Engl J Med 2009;360:411-3
   PubMed Web of Science ®Google Scholar
• Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of Clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003;107:32-7
   PubMed Web of Science ®Google Scholar
• Neubauer H, Günesdogan B, Hanefeld C, et al. Lipophilic statins interfere with the inhibitory effects of Clopidogrel on platelet function–a flow cytometry study. Eur Heart J 2003;24:1744-9
   PubMed Web of Science ®Google Scholar
• Saw J, Steinhubl SR, Berger PB, et al.; Clopidogrel for the Reduction of Events During Observation Investigators. Lack of adverse Clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled Clopidogrel trial. Circulation 2003;108:921-4
   PubMed Web of Science ®Google Scholar
• Saw J, Brennan DM, Steinhubl SR, et al. Lack of evidence of a Clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol 2007;50:291-5
   PubMed Web of Science ®Google Scholar
• Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of Clopidogrel associated with Aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256-60
   PubMed Web of Science ®Google Scholar
• Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of Clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009;301:937-44
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. High Clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J 2004;25:1903-10
   PubMed Web of Science ®Google Scholar
• Gladding P, Webster M, Zeng I, et al. The antiplatelet effect of higher loading and maintenance dose regimens of Clopidogrel. The PRINC (Plavix Response in Coronary Intervention) trial. J Am Coll Cardiol Intv 2008;1:612-9
   Web of Science ®Google Scholar
• Gladding P, Webster M, Zeng I, et al. The Pharmacogenetics and pharmacodynamics of Clopidogrel response. An analysis from the PRINC ((Plavix Response in Coronary Intervention) trial. J Am Coll Cardiol Intv 2008;1:620-7
   Web of Science ®Google Scholar
• Mehta SR, Bassand JP, Chrolavicius S, et al. Design and rationale of CURRENT-OASIS 7: a randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for Clopidogrel and Aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Am Heart J 2008;156:1080-8
   PubMed Web of Science ®Google Scholar
• von Beckerath N, Taubert D, Pogatsa-Murray G, et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of Clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: choose between 3 high oral doses for Immediate Clopidogrel Effect) Trial. Circulation 2005;112:2946-50
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Bernardo E, Sabaté M, et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2007;50:1541-7
   PubMed Web of Science ®Google Scholar
• Snoep JD, Hovens MM, Eikenboom JC, et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007;154:221-31
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Becker RC, Mann KG, et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007;50:1822-34
   PubMed Web of Science ®Google Scholar
• Anderson JL, Adamas CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non–st-elevation myocardial infarction. J Am Coll Cardiol 2007;50:e1-162
   Google Scholar
• Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after Clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006;48:2584-91
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Bhatt LD, Gurbel PA, Jennings LK. Advances in antiplatelet therapy: agents in clinical development. Am J Card 2009;103(3 Suppl):40A-51A
   PubMed Web of Science ®Google Scholar
• Niitsu Y, Jakubowski JA, Sugidachi A, Asai F. Pharmacology of CS-747 (Prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost 2005;31:184-94
   PubMed Web of Science ®Google Scholar
• Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects Prasugrel and Clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007;81:735-41
   PubMed Web of Science ®Google Scholar
• Brandt JT, Payne CD, Wiviott SD, et al. A comparison of Prasugrel and Clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007;153:66. e9-16
   PubMed Web of Science ®Google Scholar
• Jakubowski JA, Payne CD, Li YG, et al. The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following Prasugrel and Clopidogrel administration. Thromb Haemost 2008;99:409-15
   PubMed Web of Science ®Google Scholar
• Jakubowski JA, Payne CD, Li YG, et al. A comparison of the antiplatelet effects of Prasugrel and high-dose Clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry. Thromb Haemost 2008;99:215-22
   PubMed Web of Science ®Google Scholar
• Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with Clopidogrel in Aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006;27:1166-73
   PubMed Web of Science ®Google Scholar
• Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than Clopidogrel due to more efficient generation of its active metabolite in Aspirin-treated patients with coronary artery disease. Eur Heart J 2008;29:21-30
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Antman EM, Winters KJ, et al. Randomized comparison of Prasugrel (CS-747, LY640315), a novel Thienopyridine P2Y12 antagonist, with Clopidogrel in percutaneous coronary intervention results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)–TIMI 26 Trial. Circulation 2005;111:3366-73
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose Clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in comparison to Clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in Myocardial infarction 44 trial. Circulation 2007;116:2923-32
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus Clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15
   PubMed Web of Science ®Google Scholar
• Antman EM, Wiviott SD, Murphy SA, et al. Early and late benefits of Prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol 2008;51:2028-33
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504
   PubMed Web of Science ®Google Scholar
• Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined – a consensus document of the Joint European Society of Cardiology/ American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-69
   PubMed Web of Science ®Google Scholar
• New Crossover Study shows Prasugrel significantly reduced platelet aggregation in patients with acute coronary syndromes compared with Clopidogrel at high doses Eli Lilly and company. Press release archives. Available from: http://www.prnewswire.com/cgi-bin/micro_stories.pl?ACCT=916306&TICK=LLY& STORY=/www/story/09-03-2008/ 0004877390&EDATE=Sep+3,+2008 [Last accessed 11 March 2009]
   Google Scholar
• New Prasugrel head-to-head phase III study against Clopidogrel. Available from: http://www.daiichisankyo.com/4less/ cgi-bin/cs4view_obj.php/b_newsrelease_ n1_eng/382/071104v2-e.pdf [Last accessed 11 March 2009]
   Google Scholar
• Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3). Clinicaltrial.gov. Available from: http://clinicaltrials.gov/ct2/show/results/NCT00642174 [Last Accessed 11 March 2009]
   Google Scholar
• Bhatt DL. Intensifying platelet inhibition – navigating between scylla and charybdis. N Engl J Med 2007;357:2078-81
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 2008;371:1353-63
   PubMed Web of Science ®Google Scholar
• European commission approves EFIENT(R) (prasugrel) for patients with acute coronary syndrome undergoing PCI. Available from: http://newsroom.lilly.com/releasedetail.cfm?ReleaseID=366955 [Last Accessed 02 June 2009]
   Google Scholar
• Prasugrel advisory-panel controversy now has the attention of Congress. Available from: http://www.theheart.org/article/945093.do [Last Accessed 02 June 2009]
   Google Scholar
• van Giezen JJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost 2005;31:195-204
   PubMed Web of Science ®Google Scholar
• Tantry US, Bliden KP, Gurbel PA. AZD6140. Expert Opin Investig Drugs 2007;16:225-9
   PubMed Web of Science ®Google Scholar
• Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with Aspirin in patients with atherosclerosis: a double-blind comparison to Clopidogrel with Aspirin. Eur Heart J 2006;27:1038-47
   PubMed Web of Science ®Google Scholar
• Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with Clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007;50:1844-51
   PubMed Web of Science ®Google Scholar
• A comparison of AZD6140 and Clopidogrel in patients with acute coronary syndrome. Clinicaltrial.gov. Available from: http://clinicaltrials.gov/ct2/results?term=PLATO [Last accessed 11 March 2009]
   Google Scholar
• Greenbaum AB, Grines CL, Bittl JA, et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J 2006;151:689.e1-689.e10
   PubMed Web of Science ®Google Scholar
• Greenbaum AB, Ohman EM, Gibson CM, et al. Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. Am Heart J 2007;154:702-9
   PubMed Web of Science ®Google Scholar
• Champion PCI Study: comparison of IV Cangrelor to Clopidogrel in coronary stenting. Penn medicine cardiovascular institute. Available from: http://somapps.med.upenn.edu/ohr/card/viewpub.php? rc=N&type=display&pub=Y&sqlstr=protocol%20*%20804591 [Last accessed 11 March 2009]
   Google Scholar